Cross-reactivity between Candida albicans and human ovarian carcinoma as revealed by monoclonal antibodies PAI OF and C6
1998

Cross-reactivity between Candida albicans and ovarian cancer

Sample size: 37 publication Evidence: moderate

Author Information

Author(s): J Schneider, D Moragues, N Martinez, H Romero, E Jimenez, J Pontón

Primary Institution: Universidad del País Vasco

Hypothesis

Can antibodies against Candida albicans cross-react with human ovarian carcinoma?

Conclusion

The study found that a significant number of aggressive ovarian carcinomas expressed an antigen recognized by the monoclonal antibody PA1OF, suggesting a link between Candida albicans and ovarian cancer aggressiveness.

Supporting Evidence

  • 67.6% of the ovarian carcinomas tested expressed the antigen recognized by PA1OF.
  • 19 out of 24 aggressive, advanced-stage tumours were positive for the antigen.
  • Only 2 out of 13 borderline carcinomas expressed the antigen.

Takeaway

Researchers found that some antibodies made to fight a yeast called Candida albicans can also recognize and react with certain ovarian cancer cells.

Methodology

The study used immunohistochemistry to test 37 human ovarian carcinoma samples for the presence of antigens recognized by monoclonal antibodies PA1OF and C6.

Limitations

The study primarily focused on a small sample size and may not represent all ovarian cancer types.

Participant Demographics

The study involved human ovarian carcinoma samples, but specific demographic details were not provided.

Statistical Information

P-Value

0.0007

Statistical Significance

p=0.0007

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication